On thin ice: how the quest for a billion-dollar microbe is running out of control in Earth’s last wilderness

On thin ice: how the quest for a billion-dollar microbe is running out of control in Earth’s last wilderness A new UN study implies that searching for exremeophiles in areas such as the Antarctic “is threatening to plunder the planet’s last wilderness.” The body of the report, however, seems to focus on intellectual property issues. […]


Management issues challenge biotech startups

Management issues challenge biotech startups This article reviews a very interesting report that basically faults the failure of biotechnology companies to successfuly transition from research focus to product development and commercialization on hiring managers with a scientific rather than managerial forte and aiming to pass regulatory hurdles rather than build a company. Industry observations certainly […]


FDA big factor behind high US drug costs

FDA big factor behind high US drug costs The U.S. Food and Drug Administration, with its costly and time-consuming drug approval process, is a big reason Americans pay far more for medicine than consumers in the rest of the world, U.S. Nobel laureate Milton Friedman said Tuesday.


FDA Begins Push to End Drug Imports

FDA Begins Push to End Drug Imports A second ‘blitz’ inspection by federal drug and customs officials of medicines imported from Canada has found that nearly all of the almost 2,000 packages opened contained foreign versions of American pharmaceuticals that officials said might not be safe.


What To Expect From A Venture Capitalist

What To Expect From A Venture Capitalist The more important question is, ‘What can I expect out of a good venture capitalist?’ The answer to this is: five hours per month of mindshare during which he opens doors for you with prospective customers and partners and interviews candidates for high-level positions at your company.


Rise in biotech lawsuits

Rise in biotech lawsuits Biotech companies were served with 17 percent of all U.S. shareholder suits last year, according to PricewaterhouseCoopers’ Securities Litigation Study of 2003. By contrast, biotech’s estimated 350 public companies make up only 2 percent of the approximately 17,000 firms publicly traded in the United States.


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: